title: Tuberculin skin test results and the booster phenomenon in two-step tuberculin skin testing in hemodialysis patients.
abstract: Patients with chronic renal failure are at increased risk for tuberculosis (TB). Centers for Disease Control and Prevention (CDC) have recommended annual skin testing for TB, with tuberculin-purified protein derivative (PPD), in patients with chronic renal failure. Uremia alters the macrophage function, which can lead to anergy for skin tests. The aim of this prospective study was to determine the prevalence of positive tuberculin skin test (TST) and the booster effect of TST in hemodialysis patients living in a relatively underdeveloped portion of the country. Material and Methods. Patients were recruited from Van (Yuzuncu Yil University Hospital, Yuksek Ihtisas Hospital) and the Mus State Hospital). At the time of this study, a total of 143 patients were under hemodialysis treatment in these hemodialysis centers, and among them, 124 were included in the study. Informed consent was obtained before inclusion in the study. A positive PPD was an induration of >10 mm in response to five tuberculin units of PPD (RT23-Tween 80), at 72 h. TST-negative patients received a booster TST 10 days later, approximately 10 cm away from the previous intracutaneous injection. The test dose could not be increased due to unavailability of this kind of preparation. The test was performed and interpreted in the same way. Skin testing was performed in June and December 2003. Patients with known active TB are not included in the study. Testing was not done in hospitalized patients to rule out effects of other disease states. Results. Mean age of the patients was 45.3 +/- 16 (range 13-82) years. All patients were on HD treatment twice (n: 14) or three times (n: 110) weekly. Duration of dialysis before TST was 30 +/- 17 (12-84) months. With the first test (n: 14), 11.3% of the patients showed a positive reaction; the second test added (n: 15) 12.1% more TST-positive patients, reaching a total of (n: 29) 23.4% of the patients with a positive TST. The
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Yuzuncu Yil University, Medical Faculty, Van, Turkey. ekremdogan68@yahoo.com
authors.forename: Ekrem
authors.initials: E
authors.lastname: Dogan
authors.forename: Reha
authors.initials: R
authors.lastname: Erkoc
authors.forename: Hayriye
authors.initials: H
authors.lastname: Sayarlioglu
authors.forename: Kursat
authors.initials: K
authors.lastname: Uzun
mesh_terms: D017677:Age Distribution; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007117:Immunization, Secondary; D016867:Immunocompromised Host; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D008297:Male; D008403:Mass Screening / Q000379:methods; D011446:Prospective Studies; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods*; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D014373:Tuberculin; D014374:Tuberculin Test; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology*; D014421:Turkey / Q000453:epidemiology
chemical_list: D014373:Tuberculin